Bavarian Nordic Boosts 2026 Outlook on Travel Health Surge
Event summary
- Q2 2026 revenue up 23% YoY to DKK 2.034B, driven by 45% growth in Travel Health segment
- EBITDA margin expanded to 45% in Q2, up from 33% YoY, with full-year guidance raised to ~30%
- Completed DKK 500M share buyback in July, initiating new DKK 750M program
- Secured USD 97M in additional US government contracts for JYNNEOS® vaccine
- Vimkunya chikungunya vaccine launched in 14 European countries and US, with new regulatory approvals in Switzerland and Canada
The big picture
Bavarian Nordic's strong H1 2026 performance reflects a strategic pivot toward Travel Health, which now accounts for over 50% of revenue. The company's ability to secure additional government contracts for its mpox/smallpox vaccine portfolio underscores its position as a key player in public health preparedness. The upgraded full-year guidance and expanded share buyback program signal confidence in operational execution and financial discipline amid a competitive biotech landscape.
What we're watching
- Travel Health Momentum
- Whether Bavarian Nordic can sustain the 45% YoY growth in Travel Health revenue through H2 2026, particularly with RabAvert/Rabipur and Vimkunya products.
- Regulatory Expansion
- The pace at which Vimkunya gains additional regulatory approvals and market penetration, particularly in high-growth regions like Brazil.
- Public Preparedness Stability
- How Bavarian Nordic manages potential volatility in Public Preparedness revenue, given the lack of material mpox outbreak impact in 2026.
Related topics